Advertisement

EPMA Journal

, Volume 9, Issue 1, pp 1–13 | Cite as

Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine

  • Jiri PolivkaJr.
  • Irem Altun
  • Olga Golubnitschaja
Review

Abstract

The paper is motivated by severe concerns regarding currently applied care of the pregnancy-associated breast cancer (PABC) characterised by particularly poor outcomes of the disease. Psychological and ethical aspects play a crucial role in PABC: the highest priority not to damage the foetus significantly complicates any treatment generally, and it is quite usual that patients disclaim undergoing any breast cancer treatment during pregnancy. Although, due to global demographic trends, PABC is far from appearing rarely now, severe societal and economic consequences of the disease are still neglected by currently applied reactive medical approach. These actualities require creating new strategies which should be better adapted to the needs of the society at large by advancing the PABC care based on predictive diagnostic approaches specifically in premenopausal women, innovative screening programmes focused on young female populations, targeted prevention in high-risk groups, and optimised treatment concepts. The article summarises the facts and provides recommendations to advance the field-related research and medical services specifically dedicated to the PABC care.

Keywords

Predictive preventive personalised medicine Breast cancer Pregnancy Risk assessment Multi-level diagnostics Recommendations 

Notes

Authors’ contribution

OG is the project coordinator who has created the main scientific concepts presented in the manuscript. JP Jr. has performed the literature search, analysed the data, and drafted the manuscript. IA has contributed to the literature search, data collection and analysis and concepts’ development. OG and JP Jr. have designed the final version of the manuscript.

Funding information

This work was supported by the Charles University Research Fund (Progres Q39), by the MH CZ - DRO (Faculty Hospital Plzen - FNPl, 00669806), and by the National Sustainability Program I (NPU I) Nr. LO1503 provided by the Ministry of Education Youth and Sports of the Czech Republic. The authors thank the European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels) for professional and financial support of the project.

Compliance with ethical standards

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of informed consent

Patients have not been involved in the study.

Statement of human and animal rights

No experiments have been performed including patients and/or animals.

References

  1. 1.
    White TT. Carcinoma of the breast and pregnancy; analysis of 920 cases collected from the literature and 22 new cases. Ann Surg. 1954;139(1):9–18.  https://doi.org/10.1097/00000658-195401000-00002.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, et al. Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumour Biol. 2016;37(10):12941–57.  https://doi.org/10.1007/s13277-016-5168-x.PubMedCrossRefGoogle Scholar
  3. 3.
    Rodriguez AO, Chew H, Cress R, Xing G, McElvy S, Danielsen B, et al. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet Gynecol. 2008;112(1):71–8.  https://doi.org/10.1097/AOG.0b013e31817c4ebc.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim YG, Jeon YW, Ko BK, Sohn G, Kim E-K, Moon B-I, et al. Clinicopathologic characteristics of pregnancy-associated breast cancer: results of analysis of a nationwide breast cancer registry database. J Breast Cancer. 2017;20(3):264–9.  https://doi.org/10.4048/jbc.2017.20.3.264.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Langer A, Mohallem M, Stevens D, Rouzier R, Lerebours F, Chérel P. A single-institution study of 117 pregnancy-associated breast cancers (PABC): presentation, imaging, clinicopathological data and outcome. Diagn Interv Imaging. 2014;95(4):435–41.  https://doi.org/10.1016/j.diii.2013.12.021.PubMedCrossRefGoogle Scholar
  6. 6.
    Sánchez C, Acevedo F, Medina L, Ibáñez C, Razmilic D, Elena Navarro M, et al. Breast cancer and pregnancy: a comparative analysis of a Chilean cohort. Ecancermedicalscience. 2014;8:434.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Shachar SS, Gallagher K, McGuire K, Zagar TM, Faso A, Muss HB, et al. Multidisciplinary management of breast cancer during pregnancy. Oncologist. 2017;22(3):324–34.  https://doi.org/10.1634/theoncologist.2016-0208.PubMedCrossRefGoogle Scholar
  8. 8.
    Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, Dimopoulos M-A. Challenges in managing breast cancer during pregnancy. J Thorac Dis. 2013;5(Suppl 1):S62–7.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13(9):887–96.  https://doi.org/10.1016/S1470-2045(12)70261-9.PubMedCrossRefGoogle Scholar
  10. 10.
    Moreira WB, Brandão EC, Soares AN, de Lucena CEM, Antunes CMF. Prognosis for patients diagnosed with pregnancy-associated breast cancer: a paired case-control study. Sao Paulo Med J Rev Paul Med. 2010;128(3):119–24.  https://doi.org/10.1590/S1516-31802010000300003.CrossRefGoogle Scholar
  11. 11.
    American College of Pediatrics - December 2013. Information for the adolescent woman and her parents: abortion and the risk of breast cancer. Issues Law Med. 2017;32:99–104.Google Scholar
  12. 12.
    Hou N, Ogundiran T, Ojengbede O, Morhason-Bello I, Zheng Y, Fackenthal J, et al. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol. 2013;23(9):551–7.  https://doi.org/10.1016/j.annepidem.2013.06.008.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Molckovsky A, Madarnas Y. Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat. 2008;108(3):333–8.  https://doi.org/10.1007/s10549-007-9616-6.PubMedCrossRefGoogle Scholar
  14. 14.
    White TT. Carcinoma of the breast in the pregnant and the nursing patient; review of 1,375 cases. Am J Obstet Gynecol. 1955;69(6):1277–86.  https://doi.org/10.1016/S0002-9378(16)38162-5.PubMedCrossRefGoogle Scholar
  15. 15.
    Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012;379(9815):570–9.  https://doi.org/10.1016/S0140-6736(11)61092-1.PubMedCrossRefGoogle Scholar
  16. 16.
    Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St Louis J, Bukowski A, et al. Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review. Breast. 2017;35:136–41.  https://doi.org/10.1016/j.breast.2017.07.008.PubMedCrossRefGoogle Scholar
  17. 17.
    Johansson ALV, Andersson TM-L, Hsieh C-C, Jirström K, Dickman P, Cnattingius S, et al. Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat. 2013;139(1):183–92.  https://doi.org/10.1007/s10549-013-2522-1.PubMedCrossRefGoogle Scholar
  18. 18.
    Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013;138(2):549–59.  https://doi.org/10.1007/s10549-013-2437-x.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6(4):281–91.  https://doi.org/10.1038/nrc1839.PubMedCrossRefGoogle Scholar
  20. 20.
    Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N, ESMO Guidelines Working Group. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v266–73.  https://doi.org/10.1093/annonc/mdq198.PubMedCrossRefGoogle Scholar
  21. 21.
    Kakoulidis I, Skagias L, Politi E. Pregnancy associated breast cancer (PABC): aspects in diagnosis. Breast Dis. 2015;35(3):157–66.  https://doi.org/10.3233/BD-150408.PubMedCrossRefGoogle Scholar
  22. 22.
    Andersson TM-L, Johansson ALV, Hsieh C-C, Cnattingius S, Lambe M. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol. 2009;114(3):568–72.  https://doi.org/10.1097/AOG.0b013e3181b19154.PubMedCrossRefGoogle Scholar
  23. 23.
    Keyser EA, Staat BC, Fausett MB, Shields AD. Pregnancy-associated breast cancer. Rev Obstet Gynecol. 2012;5(2):94–9.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, et al. The impact of pregnancy on breast cancer outcomes in women<or=35 years. Cancer. 2009;115(6):1174–84.  https://doi.org/10.1002/cncr.24165.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    | Human Development Reports [Internet]. [cited 2018 Jan 2]. Available from: http://hdr.undp.org/en/2016-report.
  26. 26.
    Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009;14(2):87–98.  https://doi.org/10.1007/s10911-009-9119-7.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270–82.  https://doi.org/10.1056/NEJMra050776.PubMedCrossRefGoogle Scholar
  28. 28.
    Germain D. Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin N Am. 2011;40(3):473–84, vii.  https://doi.org/10.1016/j.ecl.2011.05.009.CrossRefGoogle Scholar
  29. 29.
    Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, et al. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets. 2008;8(7):597–610.  https://doi.org/10.2174/156800908786241104.PubMedCrossRefGoogle Scholar
  30. 30.
    Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007;67(5):2062–71.  https://doi.org/10.1158/0008-5472.CAN-06-3895.PubMedCrossRefGoogle Scholar
  31. 31.
    Shakhar K, Valdimarsdottir HB, Bovbjerg DH. Heightened risk of breast cancer following pregnancy: could lasting systemic immune alterations contribute? Cancer Epidemiol Biomark Prev. 2007;16(6):1082–6.  https://doi.org/10.1158/1055-9965.EPI-07-0014.CrossRefGoogle Scholar
  32. 32.
    Graham C, Chooniedass R, Stefura WP, Becker AB, Sears MR, Turvey SE, et al. In vivo immune signatures of healthy human pregnancy: inherently inflammatory or anti-inflammatory? PLoS One. 2017;12(6):e0177813.  https://doi.org/10.1371/journal.pone.0177813.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Aagaard-Tillery KM, Silver R, Dalton J. Immunology of normal pregnancy. Semin Fetal Neonatal Med. 2006;11(5):279–95.  https://doi.org/10.1016/j.siny.2006.04.003.PubMedCrossRefGoogle Scholar
  34. 34.
    Rapacz-Leonard A, Dąbrowska M, Janowski T. Major histocompatibility complex I mediates immunological tolerance of the trophoblast during pregnancy and may mediate rejection during parturition. Mediat Inflamm. 2014;2014:579279.Google Scholar
  35. 35.
    O’Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010;176(3):1241–55.  https://doi.org/10.2353/ajpath.2010.090735.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Dev Camb Engl. 1992;115:49–58.Google Scholar
  37. 37.
    Strange R, Metcalfe T, Thackray L, Dang M. Apoptosis in normal and neoplastic mammary gland development. Microsc Res Tech. 2001;52(2):171–81.  https://doi.org/10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.0.CO;2-T.PubMedCrossRefGoogle Scholar
  38. 38.
    Watson CJ, Kreuzaler PA. Remodeling mechanisms of the mammary gland during involution. Int J Dev Biol. 2011;55(7-8-9):757–62.  https://doi.org/10.1387/ijdb.113414cw.PubMedCrossRefGoogle Scholar
  39. 39.
    Martinson HA, Jindal S, Durand-Rougely C, Borges VF, Schedin P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Cancer. 2015;136(8):1803–13.  https://doi.org/10.1002/ijc.29181.PubMedCrossRefGoogle Scholar
  40. 40.
    Guo Q, Minnier J, Burchard J, Chiotti K, Spellman P, Schedin P. Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight. 2017;2:e89206.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Avishai E, Yeghiazaryan K, Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017;8(1):23–33.  https://doi.org/10.1007/s13167-017-0081-y.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Stolzenburg-Veeser L, Golubnitschaja O. Mini-encyclopaedia of the wound healing—opportunities for integrating multi-omic approaches into medical practice. J Proteomics. 2018.  https://doi.org/10.1016/j.jprot.2017.07.017.
  43. 43.
    Lenhard MS, Bauerfeind I, Untch M. Breast cancer and pregnancy: challenges of chemotherapy. Crit Rev Oncol Hematol. 2008;67(3):196–203.  https://doi.org/10.1016/j.critrevonc.2008.02.007.PubMedCrossRefGoogle Scholar
  44. 44.
    Rovera F, Chiappa C, Coglitore A, Baratelli GM, Fachinetti A, Marelli M, et al. Management of breast cancer during pregnancy. Int J Surg. 2013;11(Suppl 1):S64–8.  https://doi.org/10.1016/S1743-9191(13)60020-5.PubMedCrossRefGoogle Scholar
  45. 45.
    Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, et al. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 2012;118(13):3254–9.  https://doi.org/10.1002/cncr.26654.PubMedCrossRefGoogle Scholar
  46. 46.
    Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27(1):45–51.  https://doi.org/10.1200/JCO.2008.17.4110.PubMedCrossRefGoogle Scholar
  47. 47.
    Basaran D, Turgal M, Beksac K, Ozyuncu O, Aran O, Beksac MS. Pregnancy-associated breast cancer: clinicopathological characteristics of 20 cases with a focus on identifiable causes of diagnostic delay. Breast Care. 2014;9:355–9.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Faguy K. Breast disorders in pregnant and lactating women. Radiol Technol. 2015;86:419M–38M. quiz 439M–442MPubMedGoogle Scholar
  49. 49.
    Taylor D, Lazberger J, Ives A, Wylie E, Saunders C. Reducing delay in the diagnosis of pregnancy-associated breast cancer: how imaging can help us. J Med Imaging Radiat Oncol. 2011;55(1):33–42.  https://doi.org/10.1111/j.1754-9485.2010.02227.x.PubMedCrossRefGoogle Scholar
  50. 50.
    Aziz S, Pervez S, Khan S, Siddiqui T, Kayani N, Israr M, et al. Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma. Pathol Res Pract. 2003;199(1):15–21.  https://doi.org/10.1078/0344-0338-00347.PubMedCrossRefGoogle Scholar
  51. 51.
    Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18:1157–66.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C, et al. Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer. 1997;72(5):720–7.  https://doi.org/10.1002/(SICI)1097-0215(19970904)72:5<720::AID-IJC3>3.0.CO;2-U.PubMedCrossRefGoogle Scholar
  53. 53.
    Ishida T, Yokoe T, Kasumi F, Sakamoto G, Makita M, Tominaga T, et al. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res Gann. 1992;83(11):1143–9.  https://doi.org/10.1111/j.1349-7006.1992.tb02737.x.PubMedCrossRefGoogle Scholar
  54. 54.
    Strasser-Weippl K, Ramchandani R, Fan L, Li J, Hurlbert M, Finkelstein D, et al. Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Res Treat. 2015;149(1):255–61.  https://doi.org/10.1007/s10549-014-3219-9.PubMedCrossRefGoogle Scholar
  55. 55.
    Mielke S, Meden H, Kuhn W. Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis. Med Hypotheses. 1998;50(5):359–62.  https://doi.org/10.1016/S0306-9877(98)90205-5.PubMedCrossRefGoogle Scholar
  56. 56.
    Hsiao Y-H, Su YA, Tsai H-D, Mason JT, Chou M-C, Man Y. Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. Int J Biol Sci. 2010;6(5):428–42.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, et al. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. Springerplus. 2015;4(1):710.  https://doi.org/10.1186/s40064-015-1512-7.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet. 1998;352(9137):1359–60.  https://doi.org/10.1016/S0140-6736(05)60750-7.PubMedCrossRefGoogle Scholar
  59. 59.
    Robertson C, Primic-Zakelj M, Boyle P, Hsieh CC. Effect of parity and age at delivery on breast cancer risk in Slovenian women aged 25-54 years. Int J Cancer. 1997;73(1):1–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Trichopoulos D, Hsieh CC, MacMahon B, Lin TM, Lowe CR, Mirra AP, et al. Age at any birth and breast cancer risk. Int J Cancer. 1983;31(6):701–4.  https://doi.org/10.1002/ijc.2910310604.PubMedCrossRefGoogle Scholar
  61. 61.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95.CrossRefGoogle Scholar
  62. 62.
    Chowdhury R, Sinha B, Sankar MJ, Taneja S, Bhandari N, Rollins N, et al. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015;104:96–113.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Hadjisavvas A, Loizidou MA, Middleton N, Michael T, Papachristoforou R, Kakouri E, et al. An investigation of breast cancer risk factors in Cyprus: a case control study. BMC Cancer. 2010;10(1):447.  https://doi.org/10.1186/1471-2407-10-447.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Johansson ALV, Andersson TM-L, Hsieh C-C, Cnattingius S, Dickman PW, Lambe M. Family history and risk of pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat. 2015;151(1):209–17.  https://doi.org/10.1007/s10549-015-3369-4.PubMedCrossRefGoogle Scholar
  65. 65.
    Pollán M. Epidemiology of breast cancer in young women. Breast Cancer Res Treat. 2010;123(Suppl 1):3–6.  https://doi.org/10.1007/s10549-010-1098-2.PubMedCrossRefGoogle Scholar
  66. 66.
    Rousset-Jablonski C, Gompel A. Screening for familial cancer risk: focus on breast cancer. Maturitas. 2017;105:69–77.  https://doi.org/10.1016/j.maturitas.2017.08.004.PubMedCrossRefGoogle Scholar
  67. 67.
    Yu JH, Kim MJ, Cho H, Liu HJ, Han S-J, Ahn T-G. Breast diseases during pregnancy and lactation. Obstet Gynecol Sci. 2013;56(3):143–59.  https://doi.org/10.5468/ogs.2013.56.3.143.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer. 2005;92(1):167–75.  https://doi.org/10.1038/sj.bjc.6602302.PubMedCrossRefGoogle Scholar
  69. 69.
    Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995;4:567–71.PubMedGoogle Scholar
  70. 70.
    Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, et al. Reproductive windows, genetic loci, and breast cancer risk. Ann Epidemiol. 2014;24(5):376–82.  https://doi.org/10.1016/j.annepidem.2014.02.007.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130(2):587–97.  https://doi.org/10.1007/s10549-011-1616-x.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Millikan RC, Newman B, Tse C-K, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123–39.  https://doi.org/10.1007/s10549-007-9632-6.PubMedCrossRefGoogle Scholar
  73. 73.
    Simmen FA, Simmen RCM. The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic? Eur J Cancer Prev. 2011;20(6):539–48.  https://doi.org/10.1097/CEJ.0b013e328348fc21.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J. 2017;8(2):119–27.  https://doi.org/10.1007/s13167-017-0087-5.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2017;68(1):31–54.  https://doi.org/10.3322/caac.21440.PubMedCrossRefGoogle Scholar
  76. 76.
    Catsburg C, Miller AB, Rohan TE. Active cigarette smoking and risk of breast cancer. Int J Cancer. 2015;136(9):2204–9.  https://doi.org/10.1002/ijc.29266.PubMedCrossRefGoogle Scholar
  77. 77.
    White AJ, Bradshaw PT, Herring AH, Teitelbaum SL, Beyea J, Stellman SD, et al. Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int. 2016;89–90:185–92.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013;105(20):1571–8.  https://doi.org/10.1093/jnci/djt213.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Schottenfeld D, Jr JFF, editors. Cancer epidemiology and prevention. Third edition. Oxford: Oxford University Press; 2006.  https://doi.org/10.1093/acprof:oso/9780195149616.001.0001.Google Scholar
  80. 80.
    Richter K, Acker J, Kamcev N, Bajraktarov S, Piehl A, Niklewski G. Recommendations for the prevention of breast cancer in shift workers. EPMA J. 2011;2(4):351–6.  https://doi.org/10.1007/s13167-011-0126-6.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Blakeman V, Williams JL, Meng Q-J, Streuli CH. Circadian clocks and breast cancer. Breast Cancer Res. 2016;18(1):89.  https://doi.org/10.1186/s13058-016-0743-z.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011;77(3):430–6.  https://doi.org/10.1016/j.mehy.2011.06.002.PubMedCrossRefGoogle Scholar
  83. 83.
    Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41:2023–32.PubMedCrossRefGoogle Scholar
  84. 84.
    Wegrzyn LR, Tamimi RM, Rosner BA, Brown SB, Stevens RG, Eliassen AH, et al. Rotating night-shift work and the risk of breast cancer in the nurses’ health studies. Am J Epidemiol. 2017;186(5):532–40.  https://doi.org/10.1093/aje/kwx140.PubMedCrossRefGoogle Scholar
  85. 85.
    Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12(2):95–101.  https://doi.org/10.1023/A:1008983416836.PubMedCrossRefGoogle Scholar
  86. 86.
    Linnersjö A, Hammar N, Dammström B-G, Johansson M, Eliasch H. Cancer incidence in airline cabin crew: experience from Sweden. Occup Environ Med. 2003;60(11):810–4.  https://doi.org/10.1136/oem.60.11.810.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Pukkala E, Auvinen A, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants, 1967-92. BMJ. 1995;311(7006):649–52.  https://doi.org/10.1136/bmj.311.7006.649.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.  https://doi.org/10.1093/annonc/mdu042.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer. 2012;19(6):793–803.  https://doi.org/10.1530/ERC-12-0242.PubMedCrossRefGoogle Scholar
  90. 90.
    Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.  https://doi.org/10.1038/bjc.2012.414.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Park Y-MM, O’Brien KM, Zhao S, Weinberg CR, Baird DD, Sandler DP. Gestational diabetes mellitus may be associated with increased risk of breast cancer. Br J Cancer. 2017;116(7):960–3.  https://doi.org/10.1038/bjc.2017.34.PubMedCrossRefGoogle Scholar
  92. 92.
    Zubor P, Gondova A, Polivka J, Kasajova P, Konieczka K, Danko J, et al. Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach? EPMA J. 2017;8(2):129–40.  https://doi.org/10.1007/s13167-017-0089-3.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Bubnov R, Polivka J, Zubor P, Konieczka K, Golubnitschaja O. “Pre-metastatic niches” in breast cancer: are they created by or prior to the tumour onset? “Flammer syndrome” relevance to address the question. EPMA J. 2017;8(2):141–57.  https://doi.org/10.1007/s13167-017-0092-8.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Smokovski I, Risteski M, Polivka J, Zubor P, Konieczka K, Costigliola V, et al. Postmenopausal breast cancer: European challenge and innovative concepts. EPMA J. 2017;8(2):159–69.  https://doi.org/10.1007/s13167-017-0094-6.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. BJOG. 2012;119(13):1572–82.  https://doi.org/10.1111/j.1471-0528.2012.03475.x.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Ballard-Barbash R, Hunsberger S, Alciati MH, Blair SN, Goodwin PJ, McTiernan A, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630–43.  https://doi.org/10.1093/jnci/djp068.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Bernstein L. Exercise and breast cancer prevention. Curr Oncol Rep. 2009;11(6):490–6.  https://doi.org/10.1007/s11912-009-0066-7.PubMedCrossRefGoogle Scholar
  98. 98.
    Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, et al. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Res Treat. 2012;133(1):127–35.  https://doi.org/10.1007/s10549-011-1716-7.PubMedCrossRefGoogle Scholar
  99. 99.
    Kauppila A, Kyyrönen P, Hinkula M, Pukkala E. Birth intervals and breast cancer risk. Br J Cancer. 2009;101(7):1213–7.  https://doi.org/10.1038/sj.bjc.6605300.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482–8.  https://doi.org/10.1200/JCO.2006.07.6356.PubMedCrossRefGoogle Scholar
  101. 101.
    Fazzo L, Carere M, Tisano F, Bruno C, Cernigliaro A, Cicero MR, et al. Cancer incidence in Priolo, Sicily: a spatial approach for estimation of industrial air pollution impact. Geospat Health. 2016;11:320.PubMedCrossRefGoogle Scholar
  102. 102.
    Zimeri AM, Robb SW, Hassan SM, Hire RR, Davis MB. Assessing heavy metal and PCB exposure from tap water by measuring levels in plasma from sporadic breast cancer patients, a pilot study. Int J Environ Res Public Health. 2015;12(12):15683–91.  https://doi.org/10.3390/ijerph121215013.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Alatise OI, Schrauzer GN. Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. Biol Trace Elem Res. 2010;136(2):127–39.  https://doi.org/10.1007/s12011-010-8608-2.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Little MP, McElvenny DM. Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors—differences in excess relative and absolute risk from female breast cancer. Environ Health Perspect. 2017;125(2):223–9.  https://doi.org/10.1289/EHP151.PubMedGoogle Scholar
  105. 105.
    Grant EJ, Brenner A, Sugiyama H, Sakata R, Sadakane A, Utada M, et al. Solid cancer incidence among the life span study of atomic bomb survivors: 1958-2009. Radiat Res. 2017;187(5):513–37.  https://doi.org/10.1667/RR14492.1.PubMedCrossRefGoogle Scholar
  106. 106.
    Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.  https://doi.org/10.1038/bjc.2013.177.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Kotepui M. Diet and risk of breast cancer. Contemp Oncol Poznan Pol. 2016;20:13–9.Google Scholar
  108. 108.
    Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol. 2012;47(3):204–12.  https://doi.org/10.1093/alcalc/ags011.PubMedCrossRefGoogle Scholar
  109. 109.
    Kim HJ, Jung S, Eliassen AH, Chen WY, Willett WC, Cho E. Alcohol consumption and breast cancer risk in younger women according to family history of breast cancer and folate intake. Am J Epidemiol. 2017;186(5):524–31.  https://doi.org/10.1093/aje/kwx137.PubMedCrossRefGoogle Scholar
  110. 110.
    Härmä M, Kecklund G. Shift work and health—how to proceed? Scand J Work Environ Health. 2010;36(2):81–4.  https://doi.org/10.5271/sjweh.2902.PubMedCrossRefGoogle Scholar
  111. 111.
    Charrier A, Olliac B, Roubertoux P, Tordjman S. Clock genes and altered sleep-wake rhythms: their role in the development of psychiatric disorders. Int J Mol Sci. 2017;18(5):E938.  https://doi.org/10.3390/ijms18050938.PubMedCrossRefGoogle Scholar
  112. 112.
    Wang X-S, Armstrong MEG, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med. 2011;61(2):78–89.  https://doi.org/10.1093/occmed/kqr001.CrossRefGoogle Scholar
  113. 113.
    Schubauer-Berigan MK, Anderson JL, Hein MJ, Little MP, Sigurdson AJ, Pinkerton LE. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58(3):252–66.  https://doi.org/10.1002/ajim.22419.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Wu AH, Kurian AW, Kwan ML, John EM, Lu Y, Keegan THM, et al. Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomarkers Prev. 2015;24(2):361–8.  https://doi.org/10.1158/1055-9965.EPI-14-1140.PubMedCrossRefGoogle Scholar
  115. 115.
    Xie C, Wang W, Li X, Shao N, Li W. Gestational diabetes mellitus and maternal breast cancer risk: a meta-analysis of the literature. J Matern-Fetal Neonatal Med. 2017;7:1–11.Google Scholar
  116. 116.
    Yeghiazaryan K, Cebioglu M, Golubnitschaja O. Global figures argue in favour of preventive measures and personalised treatment to optimise inadequate diabetes care. New Strateg. Adv. PreDiabetes Care Integr. Approach PPPM [Internet]. Dordrecht : Springer; 2013 [cited 2018 Jan 23]. p. 1–13. Available from: https://link.springer.com/chapter/10.1007/978-94-007-5971-8_1.
  117. 117.
    Gaetani S, Romano A, Provensi G, Ricca V, Lutz T, Passani MB. Eating disorders: from bench to bedside and back. J Neurochem. 2016;139(5):691–9.  https://doi.org/10.1111/jnc.13848.PubMedCrossRefGoogle Scholar
  118. 118.
    Jagielska G, Kacperska I. Outcome, comorbidity and prognosis in anorexia nervosa. Psychiatr Pol. 2017;51(2):205–18.  https://doi.org/10.12740/PP/64580.PubMedCrossRefGoogle Scholar
  119. 119.
    Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–10.  https://doi.org/10.1038/nature14492.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5(1):11.  https://doi.org/10.1186/1878-5085-5-11.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, et al. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7:A25.CrossRefGoogle Scholar
  122. 122.
    Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J. 2010;1(2):263–72.  https://doi.org/10.1007/s13167-010-0032-3.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Golubnitschaja O. Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J. 2017;8(1):17–22.  https://doi.org/10.1007/s13167-017-0086-6.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Golubnitschaja O, Filep N, Yeghiazaryan K, Blom HJ, Hofmann-Apitius M, Kuhn W. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2017;  https://doi.org/10.1007/s00726-017-2524-0.
  125. 125.
    Eibye S, Kjær SK, Mellemkjær L. Incidence of pregnancy-associated cancer in Denmark, 1977-2006. Obstet Gynecol. 2013;122(3):608–17.  https://doi.org/10.1097/AOG.0b013e3182a057a2.PubMedCrossRefGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2018

Authors and Affiliations

  • Jiri PolivkaJr.
    • 1
    • 2
  • Irem Altun
    • 3
  • Olga Golubnitschaja
    • 4
    • 5
    • 6
  1. 1.Department of Histology and Embryology, Faculty of Medicine in PlzenCharles UniversityPlzenCzech Republic
  2. 2.Biomedical Centre, Faculty of Medicine in PlzenCharles UniversityPlzenCzech Republic
  3. 3.CEMBIORheinische Friedrich-Wilhelms-Universität BonnBonnGermany
  4. 4.Radiological ClinicRheinische Friedrich-Wilhelms-Universität BonnBonnGermany
  5. 5.Breast Cancer Research CentreRheinische Friedrich-Wilhelms-Universität BonnBonnGermany
  6. 6.Centre for Integrated Oncology, Cologne-BonnRheinische Friedrich-Wilhelms-Universität BonnBonnGermany

Personalised recommendations